Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corporation notice reports an intended sale of 10,000 shares of Common Stock on 07/09/2026 by Fidelity Brokerage Services LLC, reflecting a reported aggregate value of $1,550,000.00. The filing also records a stock option exercise tied to the same 10,000 shares with cash consideration on 07/09/2026.
The excerpt lists prior Rule 144 dispositions by Alex R. Thurman: 10,000 shares on 04/30/2026 for $1,400,000.00 and 10,000 shares on 07/06/2026 for $1,500,000.00. Shares outstanding are shown as 58,733,911 as of 07/09/2026.
Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman reported an exercise-and-sale transaction in company stock. On July 6, 2026, he exercised stock options for 10,000 shares of common stock at $38.68 per share and, on the same date, sold 10,000 shares of common stock in an open-market transaction at $150.00 per share. After these transactions, he directly holds 43,681 shares of Glaukos common stock, in addition to 5,230 restricted stock units that are unvested. Both the sale and the option exercise were carried out under a Rule 10b5-1 trading plan adopted on December 15, 2025, indicating they were pre-arranged rather than opportunistic market trades.
Glaukos Corp chief development officer Tomas Navratil reported a small open-market sale of company stock. On July 1, he sold 716 shares of Glaukos common stock at an average price of $139.06 per share in an open-market transaction.
After the sale, Navratil directly holds 87,634 shares of Glaukos common stock, so the transaction represents a minor portion of his overall stake. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating it was scheduled in advance. His holdings also include 38,817 restricted stock units that have not yet vested or been delivered.
Glaukos Corp. disclosure shows a reported sale transaction involving 10,000 shares of Common Stock tied to a Stock Option Exercise. The filing lists a broker/dealer Fidelity Brokerage Services LLC and dates including 04/30/2026 for a past sale and 07/06/2026 as a securities-to-be-sold date.
GKOS reported Form 144 notice related to Common Stock transactions by Tomas Navratil. The filing shows sales of $246,177.94 for 2,093 shares on 04/10/2026 and $200,855.16 for 1,537 shares on 06/16/2026. The record also lists 716 shares issued on 03/24/2025 from Restricted Stock Vesting for compensation.
Glaukos Corp chairman and CEO Thomas William Burns reported updated holdings of the company’s common stock, mainly through several family and charitable trusts. The filing lists indirect positions including 100,000 shares through the Janet M. Burns Irrevocable Trust and 1,141,593 shares through the Burns Family Trust.
The only actual share movement was a tax-withholding disposition of 4,059 directly held shares at $142.57 per share to satisfy tax obligations upon vesting and delivery of restricted stock units granted on March 18, 2021. After this, he directly holds 68,967 shares, and his position also includes 56,382 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,056 shares of common stock to cover his tax withholding obligations at $142.57 per share.
After this withholding, Gilliam directly holds 72,363 shares of common stock. This position includes 41,983 restricted stock units that have been granted but have not yet vested or been delivered, reflecting ongoing equity-based compensation rather than an open-market sale.
GLAUKOS Corp Chief Development Officer Tomas Navratil reported a small share disposition related to tax withholding, not a market sale. On this Form 4, 483 shares of common stock were withheld by the company at $142.57 per share to satisfy tax obligations upon vesting of restricted stock units granted on March 18, 2021.
After this tax-withholding event, Navratil directly holds 88,350 shares of GLAUKOS common stock, which the filing notes include 38,817 restricted stock units that have not yet vested or been delivered. This filing reflects a routine compensation and tax event rather than an open-market trade.
Glaukos Corp director Mark J. Foley reported a grant of 2,987 stock options for common stock, each with an exercise price of $106.52. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the May 28, 2026 grant date.
This Form 4/A corrects an earlier filing that mistakenly listed the exercise price as $53.57. After this grant, Foley holds 2,987 stock options from this award, which are scheduled to expire on May 28, 2036 if not exercised.
Glaukos Corp director Leana Wen received a grant of stock options, and the amended Form 4 corrects their exercise price. On May 28, 2026 she was granted options for 2,987 shares of common stock at an exercise price of $106.52 per share, expiring on May 28, 2036. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the grant date. After this grant, she holds 2,987 stock options directly.